Welcome to our dedicated page for Eton Pharmaceuticals news (Ticker: ETON), a resource for investors and traders seeking the latest updates and insights on Eton Pharmaceuticals stock.
Eton Pharmaceuticals develops and commercializes treatments for rare diseases, with commercial products that include KHINDIVI, INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. Company news commonly covers FDA approvals, product launches, licensing of U.S. commercialization rights, specialty pharmacy distribution and Eton Cares patient-support programs.
Updates also address financial results, product-sales trends, late-stage product candidates and clinical work for rare-disease therapies. Pipeline references include Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector, with ET-700 described as an extended-release zinc acetate formulation for Wilson disease.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Eton Pharmaceuticals reported Q4 2022 revenue of $8.5 million, a 39% increase from $6.1 million a year earlier. Product sales and royalty revenue surged 220% year-over-year. Net income for the quarter was $0.9 million, down slightly from $1.0 million in Q4 2021. The company experienced eighth consecutive quarters of revenue growth, primarily driven by ALKINDI SPRINKLE and Carglumic Acid. Eton has also expanded its sales force to further boost growth and plans to launch Betaine soon. Upcoming milestones include an NDA filing for a rare disease candidate, ET-600, in Q2 2024, and preparing for dehydrated alcohol injection launch.
Eton Pharmaceuticals (Nasdaq: ETON) announced the acquisition of rare disease product candidate ET-600 from Tulex Pharmaceuticals, targeting a rare pediatric endocrinology condition affecting fewer than 5,000 patients in the U.S. This acquisition aligns with Eton's strategy to expand its pediatric endocrinology portfolio. An NDA submission is anticipated in Q2 2024, potentially leading to product approval and launch in early 2025. If successful, ET-600 may provide a patent-protected revenue stream, bolstering long-term profitability for the company.
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) is set to report its fourth quarter 2022 financial results on March 16, 2023, during a conference call at 4:30 p.m. ET. The call will be accessible via a live audio webcast for investors and includes a segment for emailed questions.
Eton is focused on treatments for rare diseases and currently has three FDA-approved products: ALKINDI SPRINKLE®, Carglumic Acid tablets, and Betaine Anhydrous for Oral Solution. The company is also developing three late-stage pipeline candidates and receives royalties from other FDA-approved products.
Eton Pharmaceuticals (ETON) announced the FDA's acceptance of its New Drug Application (NDA) for dehydrated alcohol injection, aimed at treating methanol poisoning. The application has a PDUFA date set for June 27, 2023. Previously granted orphan drug designation, this product could provide Eton with seven years of exclusivity upon approval. The pharmaceutical market for dehydrated alcohol injection is significant, with trailing twelve-month sales reaching $74 million.